1
|
Hamuro L, Tirucherai GS, Crawford SM, Nayeem A, Pillutla RC, DeSilva BS, Leil TA, Thalhauser CJ. Evaluating a Multiscale Mechanistic Model of the Immune System to Predict Human Immunogenicity for a Biotherapeutic in Phase 1. AAPS JOURNAL 2019; 21:94. [PMID: 31342199 DOI: 10.1208/s12248-019-0361-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Accepted: 06/28/2019] [Indexed: 02/06/2023]
Abstract
A mechanistic model of the immune response was evaluated for its ability to predict anti-drug antibody (ADA) and their impact on pharmacokinetics (PK) and pharmacodynamics (PD) for a biotherapeutic in a phase 1 clinical trial. Observed ADA incidence ranged from 33 to 67% after single doses and 27-50% after multiple doses. The model captured the single dose incidence well; however, there was overprediction after multiple dosing. The model was updated to include a T-regulatory (Treg) cell mediated tolerance, which reduced the overprediction (relative decrease in predicted incidence rate of 21.5-59.3% across multidose panels) without compromising the single dose predictions (relative decrease in predicted incidence rate of 0.6-13%). The Treg-adjusted model predicted no ADA impact on PK or PD, consistent with the observed data. A prospective phase 2 trial was simulated, including co-medication effects in the form of corticosteroid-induced immunosuppression. Predicted ADA incidences were 0-10%, depending on co-medication dosage. This work demonstrates the utility in applying an integrated, iterative modeling approach to predict ADA during different stages of clinical development.
Collapse
Affiliation(s)
- Lora Hamuro
- Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Giridhar S Tirucherai
- Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Sean M Crawford
- Bioanalytical Sciences, Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Akbar Nayeem
- Molecular Structure and Design, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Renuka C Pillutla
- Bioanalytical Sciences, Translational Medicine, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Binodh S DeSilva
- Analytical Strategy and Operations, Product Development, Bristol-Myers Squibb, Princeton, New Jersey, 08543, USA
| | - Tarek A Leil
- Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey, 08543, USA
| | - Craig J Thalhauser
- Quantitative Clinical Pharmacology, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, New Jersey, 08543, USA.
| |
Collapse
|
2
|
Marrugal-Lorenzo JA, Serna-Gallego A, González-González L, Buñuales M, Poutou J, Pachón J, Gonzalez-Aparicio M, Hernandez-Alcoceba R, Sánchez-Céspedes J. Inhibition of adenovirus infection by mifepristone. Antiviral Res 2018; 159:77-83. [PMID: 30268911 DOI: 10.1016/j.antiviral.2018.09.011] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 09/20/2018] [Accepted: 09/26/2018] [Indexed: 11/18/2022]
Abstract
The repurposing of drugs approved by the regulatory agencies for other indications is emerging as a valuable alternative for the development of new antimicrobial therapies, involving lower risks and costs than the de novo development of novel antimicrobial drugs. Adenovirus infections have showed a steady increment in recent years, with a high clinical impact in both immunosuppressed and immunocompetent patients. In this context, the lack of a specific drug to treat these infections supports the search for new therapeutic alternatives. In this study, we examined the anti-HAdV properties of mifepristone, a commercially available synthetic steroid drug. Mifepristone showed significant in vitro anti-HAdV activity at low micromolar concentrations with little cytotoxicity. Our mechanistic assays suggest that this drug could affect the microtubule transport, interfering with the entry of the virus into the nucleus and therefore inhibiting HAdV infection.
Collapse
Affiliation(s)
- José A Marrugal-Lorenzo
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Seville, Spain
| | - Ana Serna-Gallego
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Seville, Spain
| | - Loreto González-González
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Seville, Spain
| | - Maria Buñuales
- Gene Therapy Unit CIMA, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Spain
| | - Joanna Poutou
- Gene Therapy Unit CIMA, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain
| | - Jerónimo Pachón
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Seville, Spain; Department of Medicine, University of Seville, Seville, Spain
| | - Manuela Gonzalez-Aparicio
- Gene Therapy Unit CIMA, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Spain
| | - Ruben Hernandez-Alcoceba
- Gene Therapy Unit CIMA, Foundation for Applied Medical Research, University of Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Spain.
| | - Javier Sánchez-Céspedes
- Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío/CSIC/University of Seville, Clinical Unit of Infectious Diseases, Microbiology, and Preventive Medicine, Seville, Spain; Department of Medicine, University of Seville, Seville, Spain.
| |
Collapse
|
3
|
Gómez-Mantilla JD, Trocóniz IF, Parra-Guillén Z, Garrido MJ. Review on modeling anti-antibody responses to monoclonal antibodies. J Pharmacokinet Pharmacodyn 2014; 41:523-36. [PMID: 25027160 DOI: 10.1007/s10928-014-9367-z] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Accepted: 06/25/2014] [Indexed: 10/25/2022]
Abstract
Monoclonal antibodies (mAbs) represent a therapeutic strategy that has been increasingly used in different diseases. mAbs are highly specific for their targets leading to induce specific effector functions. Despite their therapeutic benefits, the presence of immunogenic reactions is of growing concern. The immunogenicity identified as anti-drug antibodies (ADA) production due to the continuous administration of mAbs may affect the pharmacokinetics (PK) and/or the pharmacodynamics (PD) of mAbs administered to patients. Therefore, the immunogenicity and its clinical impact have been studied by several authors using PK modeling approaches. In this review, the authors try to present all those models under a unique theoretical mechanism-based framework incorporating the main considerations related to ADA formation, and how ADA may affect the efficacy or toxicity profile of some therapeutic biomolecules.
Collapse
Affiliation(s)
- José David Gómez-Mantilla
- Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, 31080, Spain
| | | | | | | |
Collapse
|